A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Cause of Unexplained Anaphylaxis
Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing
Screening Protocol for Genetic Diseases of Mast Cell Homeostasis and Activation
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
† Study has passed its completion date and status has not been verified in more than two years.